Research programme: IL1RAP antibody therapeutics - Cantargia

Drug Profile

Research programme: IL1RAP antibody therapeutics - Cantargia

Alternative Names: CAN 04; CANxx

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Lund University
  • Developer Cantargia
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 36 receptor antagonists; Interleukin-1 receptor accessory protein modulators; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic myeloid leukaemia; Solid tumours
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Jun 2017 Cantargia and Panorama Research enter into collaboration for CANxx programme for Autoimmune disorders and Inflammation
  • 12 May 2017 Cantargia files a clinical trial application to the regulatory authorities in Benelux and Scandinavia for a phase I/IIa trial in Non-small cell lung cancer and Pancreatic cancer
  • 12 May 2017 Cantargia plans the phase I/IIa CANFOUR trial in Non-small cell lung cancer and Pancreatic cancer in Benelux and Scandinavia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top